Stanford spin-out Fibralign announced that it received CE Mark approval in Europe for its BioBridge collagen matrix. Union City, Calif.-based Fibralign’s BioBridge has been designated as a Class III device with an indication for use in supporting lymphatic tissue repair and can be used after or in conjunction with surgical procedures addressing lymphedema, according to […]
Fibralign
Fibralign partners with Terumo
Stanford spin-out Fibralign announced today that it entered into a long-term distributor agreement with Terumo for the BioBridge collagen matrix. The agreement is set to see Terumo market and distribute BioBridge collagen matrix, which is used to treat and prevent secondary lymphedema, in Japan. BioBridge is a sterile, implantable, biocompatible and biodegradable surgical mesh made […]
Fibralign closes syndicate funding round from AngelMD
Fibralign has recently closed a syndicate funding round coordinated by investment and networking platform AngelMD to support its Nanoweave 3D scaffolding tech and medical devices using the technology. The Union City, Calif.-based company’s first product is the BioBridge collagen matrix, which is an implantable, biocompatible and biodegradable surgical mesh with 510(k) clearance for use in […]
Stanford launches independent study of Fibralign’s BioBridge
Stanford University has begun enrollment in an investigator-led clinical study of Fibralign‘s BioBridge collagen matrix designed for treating secondary lymphedema, the company said yesterday. The BioBridge collagen matrix is an implantable, biocompatible and biodegradable surgical mesh with 510(k) clearance for use in surgery to “reinforce and repair soft tissue where weakness and deficiencies exist,” the company said, […]
